Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 3,660 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Inhibikase Therapeutics Inc | IKT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.11 | 8.03% | 1.48 | 09:09:08 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.37 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 10 | 3,660 | - | 0.79 - 4.3512 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:10:22 | 3 | $ 1.4201 | USD |
Inhibikase Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 8.46M | 6.17M | - | 261k | -19.03M | -3.08 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Inhibikase Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IKT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.20 | 2.30 | 1.29 | 1.56 | 99,884 | -0.72 | -32.73% |
| 1 Month | 2.21 | 2.4448 | 1.29 | 1.89 | 55,651 | -0.73 | -33.03% |
| 3 Months | 3.06 | 3.35 | 1.29 | 2.45 | 103,067 | -1.58 | -51.63% |
| 6 Months | 0.94 | 3.82 | 0.7981 | 1.98 | 118,989 | 0.54 | 57.45% |
| 1 Year | 3.5688 | 4.3512 | 0.79 | 1.84 | 137,781 | -2.09 | -58.53% |
| 3 Years | 34.98 | 38.46 | 0.79 | 8.74 | 243,668 | -33.50 | -95.77% |
| 5 Years | 64.02 | 70.80 | 0.79 | 11.30 | 234,778 | -62.54 | -97.69% |
Inhibikase Therapeutics Description
| Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. |
